Most Recent
Biogen wants injunction ahead of trial against Pharmacor over MS drug
Intellectual Property 2021-08-25 2:25 pm By Cindy Cameronne

Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Court throws out Merck Sharp & Dohme’s Januvia patent extension
Intellectual Property 2021-08-12 2:29 pm By Miklos Bolza

The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Why cannot our own creations also create?’: AI can be inventor on patent, court finds
Intellectual Property 2021-07-30 12:39 pm By Cat Fredenburgh

A judge has found artificial intelligence can be named as the inventor on a patent application, setting aside an IP Australia finding that allowing a machine to be considered an inventor would render the Patents Act incapable of “sensible operation”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

After GetSwift, judge could not hear split trial in Revlimid patent case, court told
Intellectual Property 2021-07-20 8:39 pm By Christine Caulfield

A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Juno and Bristol-Myers Squibb suffer losses in Revlimid patent war
Intellectual Property 2021-03-25 1:58 pm By Miklos Bolza

A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Can artificial intelligence be named inventor of a patent? Federal Court to rule
Intellectual Property 2021-03-10 5:48 pm By Miklos Bolza

The Federal Court is set to determine whether artificial intelligence can be the inventor of a patent, after an AI pioneer filed a challenge to an IP Australia finding that allowing a machine to be considered an inventor would render the Patents Act incapable of “sensible operation”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Sandoz cross-claim seeks to block Merck Sharp & Dohme’s Januvia patent extension
Intellectual Property 2021-03-09 1:51 pm By Miklos Bolza

Generic pharmaceutical company Sandoz has hit back in an intellectual property lawsuit by Merck Sharp & Dohme, filing a cross-claim that seeks to undo an extension of time granted to the US drug manufacturer for a patent relating to its multibillion dollar Januvia and Janumet diabetes drugs.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

High Court to weigh in on $26.3M Lexapro patent judgment
High Court 2021-02-11 10:43 pm By Cat Fredenburgh

The High Court will decide whether the Full Court was wrong to overturn a $26.3 million judgment for Danish drug maker H Lundbeck in its long-running patent battle with generic drug maker Sandoz over the patent for blockbuster antidepressant Lexapro.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

The top litigation law firms of 2020
Feature 2021-01-27 11:21 pm By Cat Fredenburgh

Lawyerly’s Litigation Firms of 2020 delivered significant victories for clients last year in bet-the-company matters, thriving in a tumultuous year that saw courts and litigants adapt to virtual trials and other new norms that are sure to outlast the COVID-19 pandemic.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Tech company Sarb can amend case over Melbourne parking detector patent
Intellectual Property 2021-01-21 1:34 pm By Spencer Fowler Steen

Data technology company Sarb Management Group has been granted leave to amend its patent infringement cross claim against Vehicle Monitoring Systems in a lawsuit over Melbourne parking detectors, claiming VMS’ patents for the device should be revoked because one of its key inventors’ contribution is not recognised.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?